InvivoGen's anti-hCD20 isotype family features the variable region of either Rituximab, Ofatumumab, or Obinutuzumab clinical monoclonal antibodies (mAbs), which all target the human CD20 antigen (hCD20).
Our anti-hCD20 antibodies feature either native or engineered constant regions (Fc), which results in different capacities to exert biological functions such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), or apoptosis.
- Rituximab is a type I (first generation) mouse/human chimeric IgG1 mAb.
- Ofatumumab is a type I (first generation) fully human IgG1 mAb.
- Obinutuzumab is a type II (second generation) non-fucosylated, fully humanized IgG1 mAb.
InvivoGen's anti-hCD20 antibodies are generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography according to their isotype (protein G for IgG peptide M for IgA, and protein L for IgE/IgM).
The CD20 antigen is a transmembrane phosphoprotein that is expressed on the surface of both resting and activated B lymphocytes, but it is lost upon differentiation into plasma cells. Therefore a useful marker of B-cell lymphomas, as demonstrated in both humans and dogs.
Anti-human CD20 monoclonal antibodies (rituximab, ofatumumab, and obinutuzumab) have been approved by the FDA to treat B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL).
More isotypes are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section).
